Eric Suto

Eric Suto

Auto-generated profile, based on publicly available information

Eric Suto

Department of Translational Immunology, Genentech, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
NKNobuhiko Kayagaki
Nobuhiko Kayagaki
ISIrma B. Stowe
Irma B. Stowe
KAKamela Alegre
Kamela Alegre
IDIshan Deshpande
Ishan Deshpande
SWShuang Wu
Shuang Wu
VDVishva m Dixit
Vishva m Dixit
Plasma membrane rupture (PMR) in dying cells undergoing pyroptosis or apoptosis requires the cell-surface protein NINJ1 1 . PMR releases pro-inflammatory cytoplasmic molecules, collectively called damage-associated molecular patterns (DAMPs), that activate immune cells. Therefore, inhibiting NINJ1 and PMR may limit the inflammation that is associated with excessive cell death. Here we describe an anti-NINJ1 monoclonal antibody that specifically targets mouse NINJ1 and blocks oligomerization of NINJ1, preventing PMR. Electron microscopy studies showed that this antibody prevents NINJ1 from forming oligomeric filaments. In mice, inhibition of NINJ1 or Ninj1 deficiency ameliorated hepatocellular PMR induced with TNF plus d -galactosamine, concanavalin A, Jo2 anti-Fas agonist antibody or ischaemia–reperfusion injury. Accordingly, serum levels of lactate dehydrogenase, the liver enzymes alanine aminotransaminase and aspartate aminotransferase, and the DAMPs interleukin 18 and HMGB1 were reduced. Moreover, in the liver ischaemia–reperfusion injury model, there was an attendant reduction in neutrophil infiltration. These data indicate that NINJ1 mediates PMR and inflammation in diseases driven by aberrant hepatocellular death.

23 February 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ABAlessia Balestrini
Alessia Balestrini
VJVictory Joseph
Victory Joseph
MDMichelle Dourado
Michelle Dourado
RRRebecca M. Reese
Rebecca M. Reese
SSShannon D. Shields
Shannon D. Shields
LRLorena Riol-Blanco
Lorena Riol-Blanco
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.

4 August 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MCMichael C. Chang
Michael C. Chang
KSKarpagam Srinivasan
Karpagam Srinivasan
BFBrad A. Friedman
Brad A. Friedman
ESEric Suto
Eric Suto
ZMZora Modrusan
Zora Modrusan
MSMorgan Sheng
Morgan Sheng
Loss-of-function mutations in GRN cause frontotemporal dementia (FTD) with transactive response DNA-binding protein of 43 kD (TDP-43)–positive inclusions and neuronal ceroid lipofuscinosis (NCL). There are no disease-modifying therapies for either FTD or NCL, in part because of a poor understanding of how mutations in genes such as GRN contribute to disease pathogenesis and neurodegeneration. By studying mice lacking progranulin (PGRN), the protein encoded by GRN, we discovered multiple lines of evidence that PGRN deficiency results in impairment of autophagy, a key cellular degradation pathway. PGRN-deficient mice are sensitive to Listeria monocytogenes because of deficits in xenophagy, a specialized form of autophagy that mediates clearance of intracellular pathogens. Cells lacking PGRN display reduced autophagic flux, and pathological forms of TDP-43 typically cleared by autophagy accumulate more rapidly in PGRN-deficient neurons. Our findings implicate autophagy as a novel therapeutic target for GRN-associated NCL and FTD and highlight the emerging theme of defective autophagy in the broader FTD/amyotrophic lateral sclerosis spectrum of neurodegenerative disease.

2 June 2020 in Science Signaling
Verified
Journal Article
Open access
PDF file
CCCesar A. Corzo
Cesar A. Corzo
EVEugene Varfolomeev
Eugene Varfolomeev
ASA. Francesca Setiadi
A. Francesca Setiadi
RFRoss Francis
Ross Francis
SKSha Klabunde
Sha Klabunde
AZAli A. Zarrin
Ali A. Zarrin
Inhibiting the kinase IRAK4 may suppress a multicellular autoinflammatory loop in patients with lupus.

14 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKArna Katewa
Arna Katewa
ESEric Suto
Eric Suto
JHJessica Hui
Jessica Hui
JHJose Heredia
Jose Heredia
JLJie Liang
Jie Liang
NGNico Ghilardi
Nico Ghilardi
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease representing a serious unmet medical need. The disease is associated with the loss of self-tolerance and exaggerated B cell activation, resulting in autoantibody production and the formation of immune complexes that accumulate in the kidney, causing glomerulonephritis. TLR7, an important mediator of the innate immune response, drives the expression of type-1 interferon (IFN), which leads to expression of type-1 IFN induced genes and aggravates lupus pathology. Because the lysosomal peptide symporter slc15a4 is critically required for type-1 interferon production by pDC, and for certain B cell functions in response to TLR7 and TLR9 signals, we considered it as a potential target for pharmacological intervention in SLE. We deleted the slc15a4 gene in C57BL/6, NZB, and NZW mice and found that pristane-challenged slc15a4-/- mice in the C57BL/6 background and lupus prone slc15a4-/- NZB/W F1 mice were both completely protected from lupus like disease. In the NZB/W F1 model, protection persisted even when disease development was accelerated with an adenovirus encoding IFNα, emphasizing a broad role of slc15a4 in disease initiation. Our results establish a non-redundant function of slc15a4 in regulating both innate and adaptive components of the immune response in SLE pathobiology and suggest that it may be an attractive drug target.

21 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HDHart S. Dengler
Hart S. Dengler
XWXiumin Wu
Xiumin Wu
IPIvan Peng
Ivan Peng
CRCornelia H. Rinderknecht
Cornelia H. Rinderknecht
YKYoungsu Kwon
Youngsu Kwon
NGNico Ghilardi
Nico Ghilardi
Inhalation of a Janus kinase 1 inhibitor suppressed lung inflammation without systemic side effects in rodent models of asthma.